Nivolumab + ipilimumab + 2 cycles of platinum doublet
Checked 2026-09-09
Metastatic NSCLC without EGFR/ALK alteration, first line
One cycle
every 21 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Nivolumab Monoclonal antibody (anti-PD-1) | 360 mg | IV | D1 | |
Ipilimumab Monoclonal antibody (anti-CTLA-4) | 1 mg/kg every 6 weeks | IV | D1 | alternate cycles |
Platinum doublet by histology Cytotoxic chemotherapy (platinum) | cycles 1-2 only | IV | D1 |
Cycles
chemotherapy 2; nivolumab up to 2 years
21-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Used in
Products
Source
CheckMate 9LA, Lancet Oncology 2021
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Trastuzumab deruxtecan 5.4 mg/kg
HER2-positive metastatic breast cancer second line; HER2-low or ultralow after chemotherapy or endocrine therapy; HER2-mutant NSCLC
every 21 days
Pembrolizumab + pemetrexed + platinum
Metastatic non-squamous NSCLC without EGFR/ALK alteration, first line, any PD-L1
every 21 days × 4
Pembrolizumab + carboplatin + paclitaxel
Metastatic squamous NSCLC, first line
every 21 days × 4
Osimertinib
EGFR ex19del or L858R NSCLC: first line metastatic (FLAURA), adjuvant for 3 years after resection (ADAURA), after chemoradiation (LAURA)
every 28 days
Cisplatin + vinorelbine (adjuvant)
Completely resected stage IB (4 cm or larger) to IIIA NSCLC
every 28 days × 4
Chemoradiation then durvalumab (PACIFIC)
Unresectable stage III NSCLC without progression after platinum-based chemoradiation
every 28 days × 12
Cisplatin + etoposide (EP)
Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma
every 21 days × 4
Cisplatin + pemetrexed
Unresectable pleural mesothelioma (with or without bevacizumab); non-squamous NSCLC
every 21 days × 6